Navigation Links
Recruitment Completed in Ofatumumab NHL Pivotal Study
Date:9/23/2008

as measured over a 6 month period from start of treatment assessed by an Independent endpoints Review Committee (IRC) according to the standardized criteria for NHL.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements.

The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
3. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
4. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
5. Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment
6. Argonauta Assist(TM)ance: Argonauta Communications Strives to Enhance Site-Based Recruitment Efforts
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
9. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
10. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
11. Genmab Reaches Milestone in Ofatumumab Collaboration

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...e/-- ChemoCentryx,Inc.,announcedtodaythatPhaseII/...ctiveRandomizedOralTherapyEvaluationinCrohn,sdisea...oderate-to-severeCrohn,sdiseasedemonstratedclinica...e.Thestudydemonstratedevidenceofclinicalefficacyin...ecreaseintheCrohn,sDiseaseActivityIndex(CDAI)inpat...
(Date:11/24/2009)..., WHAT:RomHoubens,aBelgianmanthoughttohavebeeninco...lyconsciousandawakeduringthattimeandwasthesubjecto...turedinthesegmenttoillustratehowpeoplewithLocked-i... ,, WHEN:GoodMorningAmerica-- Tuesday,November2..., WHO:RomHoubenswasanengineeringstudentin1986when...
(Date:11/24/2009)...Call/--QuestDiagnosticsIncorporated(NYSE: DGX ),th...tionandservices,announcedthatitisscheduledtospeaka...wYorkCity.ThepresentationisscheduledforWednesday,D...econference,thecompanywillreaffirmits2009guidancef...ceed18%ofrevenues,anddilutedearningspersharefromco...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 1 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 2 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 4 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 5 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 6AlphaHelix Presents AmpXpress 28TM 29 at the BIOTECHNICA Show 14356 1AlphaHelix Presents AmpXpress 28TM 29 at the BIOTECHNICA Show 14356 2US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 1US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 2US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 3
...orporation (Nasdaq:,DNDN) today will present a sum...uleucel-T), an investigational active cellular imm...um in New York City. The presentation, which,integ...s the safety,profile, immune response and clinical...sitive cancer who have failed standard therapy., ...
...Pharmaceuticals,Inc. (Nasdaq: VIAP ), a biotechno...ds for the treatment of cardiovascular disease, an...and webcast to discuss results of the,VIA-2291 Pha...arterectomy,(CEA) trials presented at the American...on Sunday, November 9. The conference call and web...
Other Medicine Technology:Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 2Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 3Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 4VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA 2
(Date:11/25/2009)...ov.25/PRNewswire/-SentinelleMedicalInc.,aleadingma...oftwareandCalgaryScientificInc.,aleadingproviderof...sionofAegis(TM)Breast4DAdvancedVisualizationsoftwa...ro-footprintWebclientbasedmedicalimagingofferingin...lowsforzero-footprintaccess-requiringnosoftwaredow...
(Date:11/25/2009).../PRNewswire/--TheBayAreaAirQualityManagementDistri... Air Alert forThursday,November26,2009whic...idfuel,bothindoorsandoutdoors. ,, "Cold,stillwe...saidJackBroadbent,executiveofficeroftheAirDistrict...heirneighborsandfellowcommunitymembersthisThanksgi...
(Date:11/25/2009)...d pressure? This simple question has been the foc...-related gene Modulates High Blood Pressure in Mic...is simple question has been the focus of intense r...the first time established a link between a novel ...o stress in mice as well as humans. The studies we...
(Date:11/25/2009)...neurological symptoms, study finds , , ...l side effects are among the potential problems fa...o were treated with cisplatin-based chemotherapy, ...09 Norwegian men treated for unilateral testicular...ollow-up survey conducted from 1998 to 2002. , ...
(Date:11/25/2009)...cer vaccine carried into the body on a carefully e...o successfully eliminate tumors in mammals, scient...slational Medicine . , The new approach, pioneer...iversity, uses plastic disks impregnated with tumo...o reprogram the mammalian immune system to attack ...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2
...ssue of the journal Thorax, researchers have empha... Researchers have looked into the data provided ...m connection between smoking and incidence of tube...e of the risk of acquiring Mycobacterium tuberculo...
...t by outsiders as the land of mystic magic, serine...al key to getting in touch with the spiritual side... sub-continent then what meets the eye at first gl...ay. 1,500 persons effected with the virus die here...
...ministration (FDA) issued a public health advisory...bout the suspended marketing of Tysabri (nataluzim...tiple sclerosis (MS) which was approved by the FDA... it is believed that the drug has a promising role...
...emical compounds like marijuana that can help the ...ere trauma // like accidents. Scientists hav... gun shot, or accidents causing severe damage to b... Scientists working for University of Georgia h...
...f Michigan, who had long earlier published their f...dhood and having ADHD, have come up with the resul...ly links the association between the two. Th... as likely to have hyperactivity problem than thei...
...r nimesulide, a controversial non-steroidal anti-i...ever and pain the health ministry admitted that dr...ory agency and not evaluated for effectiveness are...of nimesulide among children. The group had also o...
Other Medicine News:Health News:AIDS - The ‘silent but lethal tsunami’ of Asia 2
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
Medicine Products: